AOBiome announces appointment of scientific advisory board

Latest News


AOBiome announces appointment of scientific advisory board


19 May 2014, Cambridge, MA
AOBiome, a company pioneering potentially transformative healthcare products based on modulating the skin microbiome, announced today the establishment of a Scientific Advisory Board to help guide the company’s programs for developing proprietary probiotic cosmetics to enhance skin health and novel therapeutics to prevent or treat skin and inflammatory diseases.

“AOBiome is building on the rapidly emerging science of the skin microbiome to advance a new category of skin products by applying “good bacteria” to restore the natural, protective balance of skin microbes,” said Spiros Jamas, ScD, CEO of AOBiome. “We have assembled world leaders in genomics and sequencing; dermatology; nitric oxide biology; immunology; and wound healing physiology to help guide the company’s efforts. We look forward to many contributions from this distinguished group.”

AOBiome’s lead probiotic oxidizes ammonia, which is abundant in sweat, to produce nitrite and nitric oxide, which are essential to good health. “These ammonia oxidizing bacteria (AOB) have been eliminated by most soaps and frequent use of antibiotics. Reintroducing AOB may provide important benefits by restoring the natural balance of formation and degradation of nitric oxide needed to regulate key pathways known to be perturbed in skin and inflammatory diseases,” commented Martin Feelisch, PhD, Professor of Experimental Medicine and Integrative Biology at the University of Southampton (UK).

Members of the AOBiome Scientific Advisory Board include:
George Church, PhD, Professor of Genetics, Harvard Medical School, Professor of Health Sciences and Technology at Harvard and MIT Martin Feelisch, PhD, Professor of Experimental Medicine and Integrative Biology at the University of Southampton (UK). Howard Maibach, MD, Professor of Dermatology, UCSF School of Medicine Dean Ornish, MD, Founder & President of the nonprofit Preventative Medicine Research Institute and Clinical Professor of Medicine, University of California San Francisco Derya Unutmaz, MD, Professor of Microbiology, Pathology and Medicine, Director of Human Immunology & shRNA Core, NYU School of Medicine Aristidis Veves, MD, DSc, Professor, Harvard Medical School; Research Director, Microcirculation Lab & Joslin-Beth Israel Deaconess Foot Center Larry Weiss, MD, Founder & Chief Scientist, CleanWell Company

About AOBiome
AOBiome LLC is developing a transformative, new class of products based on Ammonia Oxidizing Bacteria (AOB) to improve skin health and prevent or treat skin and inflammatory diseases. The company’s probiotics are designed to provide cosmetic and therapeutic benefits by restoring the natural, protective balance afforded by beneficial skin microbes that have been lost due to modern living practices, including antibiotic use, soaps, and shampoos. AOB are ubiquitous bacteria that use oxidize ammonia and urea, two components in sweat, to nitrite, an anti-microbial compound, and nitric oxide, an important signaling molecule that helps the body manage skin and systemic functions. AOBiome is developing cosmetics and a pipeline of skin therapeutics to treat diabetic ulcers, acne and atopic dermatitis.

The company was established in 2013 by its scientific founder, David Whitlock; biotech entrepreneur James Heywood, Co-founder of PatientsLikeMe and Founder of the ALS Therapy Development Institute; Lenny Barshack, a serial entrepreneur of technology companies; and Dr. Jamas.




Recent News
19 October 2017, Cambridge, MA
AOBiome Therapeutics Reports Positive Efficacy Results from Phase 2b Clinical Trial of Ammonia Oxidizing Bacteria (AOB) for the Treatment of Acne Vulgaris

3 October 2017, Cambridge, MA
AOBiome Commences Patient Enrollment in Phase 1b/2a Clinical Trial of Ammonia Oxidizing Bacteria (AOB) for the Treatment of Seasonal Allergic Rhinitis

20 September 2017, Cambridge, MA
AOBiome Expands Intellectual Property Estate, Announces Issuance of U.S. Patent for Ammonia Oxidizing Bacteria (AOB) for the Treatment of Acne

13 April 2017, Cambridge, MA
AOBiome Completes Patient Enrollment In Phase 2 Clinical Trial Of Lead Candidate B244 To Treat Elevated Blood Pressure

4 March 2017, Cambridge, MA
American Academy of Dermatology selects AOBiome study for presentation at Annual Meeting

5 January 2017, Cambridge, MA
AOBiome Partners with iCarbonX and Secures $30 Million Investment for Drug Development

16 December 2016, Cambridge, MA
AOBiome Launches Phase 2 Clinical Trial Using Novel Bacterial Platform for Treatment of Hypertension

20 September 2016, Cambridge, MA
AOBiome Announces First-of-its Kind Trial of Live Topical Bacterial Treatment for Acne

31 December 2015, Cambridge, MA
AOBiome Wins Dermatology Entrepreneurship Shark Tank Contest

7 July 2015, Cambridge, MA
Mother Dirt Rethinks what it means to be Clean and Healthy with First-Ever Line of Biome-Friendly Products for the Skin

29 June 2015, Cambridge, MA
AOBiome co-founder, Jamie Heywood named by Scientific American, as one of The Worldview 100, The visionaries who continue to reshape biotechnology-and the world

22 June 2015, Cambridge, MA
AOBiome Announces Start of First Clinical Trial with Ammonia Oxidizing Bacteria-Based Therapeutic for Treatment of Acne

18 May 2015, Cambridge, MA
AOBiome Announces Three Senior Management Appointments

2 Oct 2014, Washington, DC
American Society for Microbiology Reports Sweat-Eating Bacteria May Improve Skin Health

20 Jun 2014, Cleveland, OH
Accelerated Healing of Diabetic Ulcer Data Presented

16 Jun 2014, Cambridge, MA
AOBiome in the News

19 May 2014, Cambridge, MA
AOBiome announces appointment of scientific advisory board

30 Jun 2013, Cambridge, MA
Nitrocell becomes AOBiome LLC